Advances in the treatment of hepatitis C in children and adolescents
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Progress is being made in the treatment of hepatitis C virus (HCV) infection in adults. The current recommended strategy is to use the combination of pegylated-interferon and ribavirin, which leads to a sustained virologic response rate in 50% to 60% of individuals eligible for treatment. Less is known about HCV infection in the pediatric population. Recently, small and uncontrolled studies have suggested that combination therapy of interferon alpha with ribavirin improves the outcome of HCV-infected children. There are no data yet regarding the use of pegylated interferons in pediatrics. This article summarizes what is known about the treatment of HCV in children and adolescents, and discusses future areas of research as they may pertain to the idiosyncrasies of the pediatric population.
- United States National Institute of Diabetes & Digestive & Kidney Diseases: NIH Action Plan for Liver Disease Research. http://www.niddk.nih.gov/fund/divisions/ddn/ldrb/ldrb_action_plan.htm. Accessed February 20, 2005.
- Jara P, Resti M, Hierro L, et al.: Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children. Clin Infect Dis 2003, 36:275–280. CrossRef
- Hochman JA, Balistreri WF: Chronic viral hepatitis: always be current! Pediatr Rev 2003, 24:399–410.
- Bortolotti F, Jara P, Diaz C, et al.: Posttransfusion and communityacquired hepatitis C in childhood. J Pediatr Gastroenterol Nutr 1994, 18:279–283. CrossRef
- Vogt M, Lang T, Frosner G, et al.: Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood donor screening. N Engl J Med 1999, 341:866–870. CrossRef
- Casiraghi M, De Paschale M, Romanò L, et al.: Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions given at birth. Hepatology 2004, 39:90–96. CrossRef
- Guido M, Bortolotti F, Leandro G, et al.: Fibrosis in chronic hepatitis C acquired in infancy: is it only a matter of time? Am J Gastroenterol 2003, 98:660–663. CrossRef
- Rerksuppaphol S, Hardikar W, Dore GJ: Long-term outcome of vertically acquired and post-transfusion hepatitis C infection in children. J Gastroenterol Hepatol 2004, 19:1357–1362. CrossRef
- Sinha M, Das A: Cost-effectiveness analysis of different strategies of management of chronic hepatitis C infection in children. Pediatr Infect Dis J 2000, 19:23–30. CrossRef
- Gonzalez-Peralta RP: Treatment of chronic hepatitis C in children. Pediatr Transplant 2004, 8:639–643. Excellent review of treatment modalities and results to date. CrossRef
- Jacobson KR, Murray K, Zellos A, Schwarz KB: An analysis of published trials of interferon monotherapy in children with chronic hepatitis C. J Pediatr Gastorenterol Nutr 2002, 34:52–58. CrossRef
- Carithers RI, Emerson SS: Therapy of hepatitis C: metaanalysis of interferon alfa-2b trials. Hepatology 1997, 26(suppl):83S-88S. CrossRef
- McHutchinson JG, Gordon SC, Schiff ER, et al.: Interferon alpha 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis C Interventional Therapy Group. N Engl J Med 1998, 339:1485–1492. CrossRef
- Brillanti S, Miglioli M, Barbara L: Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience. J Hepatol 1995, 23(suppl 2):13–15; discussion 15–16.
- Kelly D, Bunn S, Apelian D, et al.: Safety, efficacy, and pharmacokinetics of interferon alfa-2b plus ribavirin in children with chronic hepatitis C. Hepatology 2001, 34:680A.
- Wirth S, Lang T, Ghering S, Gerner P: Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. Hepatology 2002, 36:1280–1284. CrossRef
- Christensson B, Wiebe T, Akesson A, Widell A: Interferonalpha and ribavirin treatment of hepatitis C in children with malignancy in remission. Clin Infect Dis 2000, 30:585–586. CrossRef
- Lackner H, Moser A, Deutsch J, et al.: Interferon-alpha and ribavirin in treating children and young adults with chronic hepatitis C after malignancy. Pediatrics 2000, 106:E53. CrossRef
- Suoglu OD, Elkabes B, Sokucu S, Saner G: Does interferon and ribavirin combination therapy increase the rate of treatment response in children with hepatitis C? J Pediatr Gastroenterol Nutr 2002, 34:199–206. CrossRef
- Hartman C, Berkowitz D, Rimon N, Shamir R: The effect of early treatment in children with chronic hepatitis. J Pediatr Gastroenterol Nutr 2003, 37:252–257. CrossRef
- Schwarz KB, Mohan P, Narkewicz M, et al.: The safety, efficacy and pharmacokinetics of peginterferon alfa-2a (40 kD) in children with chronic hepatitis C. Gastroenterology 2003, 124:A700. CrossRef
- Hoofnagle JH: Peds-C. Hepatology 2005, 41:421. CrossRef
- Li DY, Schwarz KB: Immunopathogenesis of chronic hepatitis C virus infection. J Pediatr Gastroenterol Nutr 2002, 35:260–267. CrossRef
- Strader DB, Wright T, Thomas DL, et al.: Diagnosis, management, and treatment of hepatitis C. Hepatology 2004, 39:1147–1171. CrossRef
- Scotto G, Palumbo E, Fazio V: Peginterferon alfa-2b treatment for patients affected by acute hepatitis C: presentation of six case reports. Infection 2005, 33:30–32. CrossRef
- Nowicki MJ, Ahmad N, Heubi J, et al.: The prevalence of hepatitis C virus (HCV) in infants and children after liver transplantation. Dig Dis Sci 1994, 39:2250–2254. CrossRef
- McDiarmid SV, Conrad A, Ament ME, et al.: De novo hepatitis C in children after liver transplantation. Transplantation 1998, 66:311–318. CrossRef
- Barlow CF, Priebe CJ, Mulliken JB, et al.: Spastic diplegia as a complication of interferon alfa2a treatment of hemangiomas in infancy. J Pediatr 1998, 132:527–530. CrossRef
- Hardikar W: Hepatitis C in childhood. J Gastroenterol Hepatol 2002, 17:476–481. CrossRef
- Mofenson LM, Oleske J, Serchuck L, et al.: Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. Clin Infect Dis 2005, 40(suppl 1):S1-S84. CrossRef
- Iorio R, Pensati P, Botta S, et al.: Side effects of alpha-interferon therapy and impact on health-related quality of life in children with chronic viral hepatitis. Pediatr Infect Dis J 1997, 16:984–990. CrossRef
- Martinot-Peignoux M, Boyer N, Pouteau M, et al.: Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. J Hepatol 1998, 29:214–223. CrossRef
- National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C [no authors listed]. Hepatology. 1997, 26:2S–10S.
- Murray KF, Richardson LP, Morishima C, et al.: Prevalence of hepatitis C infection and risk factors in an incarcerated juvenile population: a pilot study. Pediatrics 2003, 111:153–157. CrossRef
- Hugle T, Cerny A: Current therapy and new molecular approaches to antiviral treatment and prevention of hepatitis C. Rev Med Virol 2003, 13:361–371. Review of ongoing areas of research in the field of hepatitis C treatment. CrossRef
- Rockey DC: Antifibrotic therapy in chronic liver disease. Clin Gastroenterol Hepatol 2005, 3:95–107. CrossRef
- Delgado-Borrego A, Jonas MM: Treatment options for hepatitis C infection in children. Curr Treat Options Gastroenterol 2004, 7:373–379. Practical guide to the management of pediatric hepatitis C according to the U.S. Food and Drug Administration guidelines combining IFN alpha with ribavirin.
- Hepatitis C. In Red Book Online. Edited by Pickering, LK. Elk Grove Village, IL: American Academy of Pediatrics; 2003: 336–340. http://aapredbook.aappublications.org/cgi/content/full/2003/1/3.52
- Gibb DM, Goodall RL, Dunn DT, et al.: Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet 2000, 356:904–907. CrossRef
- Steininger C, Kundi M, Jatzko G, et al.: Increased risk of mother-to-infant transmission of hepatitis C virus by intrapartum infantile exposure to maternal blood. J Infect Dis 2003, 187:345–351. CrossRef
- Okamoto M, Nagata I, Murakami J, et al.: Prospective reevaluation of risk factors in mother-to-child transmission of hepatitis C virus: high virus load, vaginal delivery, and negative anti-NS4 antibody. J Infect Dis 2000, 182:1511–1514. CrossRef
- Mast EE: Mother-to-infant hepatitis C virus transmission and breastfeeding. Adv Exp Med Biol 2004, 554:211–216.
- Hickman IJ, Powell EE, Prins JB, et al.: In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J Hepatol 2003, 39:1042–1048. CrossRef
- Hourigan LF, Macdonald GA, Purdie D, et al.: Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999, 29:1215–1219. CrossRef
- Thomopoulos KC, Theocharis GJ, Tsamantas AC, et al.: Liver steatosis is an independent risk factor for treatment failure in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 2005, 17:149–153. CrossRef
- Bruno R, Sacchi P, Maiocchi L, et al.: Host factors affecting the outcome of treatment of hepatitis C. Rev Gastroenterol Disord 2004, 4(suppl 1):S3-S7.
- Advances in the treatment of hepatitis C in children and adolescents
Current Hepatitis Reports
Volume 4, Issue 3 , pp 97-103
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links